{
    "id": "b8c6f558-9cbd-4389-a8d7-a8c698c49093",
    "code": {
        "code": "34391-3",
        "codeSystem": "2.16.840.1.113883.6.1",
        "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
    },
    "name": "Tyrvaya",
    "organization": "Oyster Point Pharma, Inc.",
    "effectiveTime": "20240212",
    "ingredients": [
        {
            "name": "VARENICLINE TARTRATE",
            "code": "82269ASB48"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE",
            "code": "70WT22SF4B"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS",
            "code": "KH7I04HPUU"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "1 usage tyrvaya ( varenicline solution ) nasal spray indicated treatment signs symptoms dry eye disease. tyrvaya ( varenicline solution ) nasal spray cholinergic agonist indicated treatment signs symptoms dry eye disease. ( 1 )",
    "contraindications": "4 none none.",
    "warningsAndPrecautions": null,
    "adverseReactions": "6 common reaction reported 82% patients sneezing. events reported 5-16% patients cough, throat irritation, instillation-site ( nose ) irritation. ( 6 ) report suspected reactions, contact oyster point pharma 1-877-eye-0123 fda 1-800-fda-1088 www.fda.gov/medwatch. 6.1 trials experience trials conducted widely varying conditions, reaction rates observed trials cannot directly compared rates trials another may reflect rates observed practice. three dry eye disease conducted varenicline solution nasal spray, 349 patients received least 1 dose tyrvaya. majority patients 31 days treatment exposure, maximum exposure 105 days. common reported 82% tyrvaya treated patients sneezing. common reported >5% patients include cough ( 16% ) , throat irritation ( 13% ) , instillation-site ( nose ) irritation ( 8% ) .",
    "indications_original": "1 INDICATIONS AND USAGE TYRVAYA (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease. TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )",
    "contraindications_original": "4 CONTRAINDICATIONS None None.",
    "adverseReactions_original": "6 ADVERSE REACTIONS The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Oyster Point Pharma at 1-877-EYE-0123 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In three clinical studies of dry eye disease conducted with varenicline solution nasal spray, 349 patients received at least 1 dose of TYRVAYA. The majority of patients had 31 days of treatment exposure, with a maximum exposure of 105 days. The most common adverse reactions reported in 82% of TYRVAYA treated patients was sneezing. Other common adverse reactions that were reported in >5% of patients include cough (16%), throat irritation (13%), and instillation-site (nose) irritation (8%)."
}